BIOMAT Database Logo BIOMAT Database Logo

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. 2020

Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.

UI MeSH Term Description Entries
D009534 Niclosamide An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48) Bayer 2353,Bayer 73,Bayluscide,Clonitralide,Fenasal,Niclocide,Niclosamide, 2-Aminoethanol (1:1),Phenasal,Radewerm,Trédémine,Yomesan
D011024 Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection. Pneumonias, Viral,Viral Pneumonia,Viral Pneumonias
D011282 Pregnenediones Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures. Diketopregnenes,Dioxopregnenes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000073640 Betacoronavirus A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of mostly mammals. Human betacoronaviruses include HUMAN ENTERIC CORONAVIRUS; HUMAN CORONAVIRUS OC43; MERS VIRUS; and SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS. Members have either core transcription regulatory sequences of 5’-CUAAAC-3’ or 5’-CUAAAC-3’ and mostly have no ORF downstream to the N protein gene. HCoV-HKU1,Human coronavirus HKU1,Pipistrellus bat coronavirus HKU5,Rousettus bat coronavirus HKU9,Tylonycteris bat coronavirus HKU4,Betacoronaviruses
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19

Related Publications

Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
May 2020, mBio,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs.
April 2022, Journal of biomolecular structure & dynamics,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.
June 2021, Journal of pharmaceutical sciences,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.
June 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
May 2021, Clinical and translational science,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.
January 2021, International journal of peptide research and therapeutics,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Antiviral drugs against SARS-CoV-2.
October 2022, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
January 2020, Frontiers in immunology,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening.
January 2023, Structural chemistry,
Sangeun Jeon, and Meehyun Ko, and Jihye Lee, and Inhee Choi, and Soo Young Byun, and Soonju Park, and David Shum, and Seungtaek Kim
A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2.
February 2023, Journal of biomolecular structure & dynamics,
Copied contents to your clipboard!